Crescent Sterling Ltd. Has $438,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Crescent Sterling Ltd. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 417 shares of the biopharmaceutical company’s stock after selling 16 shares during the period. Crescent Sterling Ltd.’s holdings in Regeneron Pharmaceuticals were worth $438,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Global Assets Advisory LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $339,594,000. Capital International Investors boosted its position in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the last quarter. TD Asset Management Inc boosted its position in Regeneron Pharmaceuticals by 162.9% in the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock worth $259,402,000 after purchasing an additional 166,998 shares during the last quarter. Finally, Swedbank AB purchased a new position in Regeneron Pharmaceuticals in the first quarter worth $129,257,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Royal Bank of Canada boosted their price objective on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Truist Financial reissued a “buy” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 9th. Finally, Barclays boosted their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,119.00.

Regeneron Pharmaceuticals Trading Up 0.2 %

Shares of REGN stock opened at $1,016.53 on Wednesday. The stock has a market capitalization of $112.01 billion, a PE ratio of 30.03, a P/E/G ratio of 3.45 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The business has a 50-day moving average of $1,115.89 and a 200 day moving average of $1,040.15. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the business posted $8.79 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.82 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.